The present invention relates to settable compositions for use in surgery. The invention also provides related compositions, including surgical kits and packages, as well as methods of making and using the settable compositions.

To provide an agent for hypodermic injection that has excellent flow characteristics, can be used particularly even in thin injection needles, for example with an internal diameter of 0.20 mm or less, and is unlikely to cause pain during injection and inflammation.

The agent for hypodermic injection includes a hydrogel containing sintered hydroxyapatite particles, wherein the sintered hydroxyapatite particle content is 1 to 60% by mass based on the total mass of the agent, and the average particle diameter of the sintered hydroxyapatite particles is 15 μm or less.

Medical devices having engineered mechanically functional cartilage from adult human mesenchymal stem cells and method for making same.

Medical devices having engineered mechanically functional cartilage from adult human mesenchymal stem cells and method for making same.

The present disclosure provides a biomaterial and a method for promoting tissue regeneration by using the biomaterial.

The present invention relates to bone repair material of multivariant amino acid polymer-hydroxyapatite, supportive implants and preparation method. Said restorative material is made of multivariant amino acid polymers consisted with ε-aminocaproic acid and other α-amino acids, together with constituents modified hydroxyapatite, in which the constituent modified hydroxyapatite uses calcium salt as modified constituents that can be accepted in medicine and has a more solubility compared with hydroxyapatite. Modified hydroxyapatite is constructed from said calcium salt and hydroxyapatite, with a mass ratio of (2-20):(98-80), and the content of modified hydroxyapatite is 10-70% based on the mass of said bone repair material; the content of ε-aminocaproic acid in multivariant amino acid polymers is 60-99% based on the total molar quantity of multivariant amino acid polymers.

The present invention relates to bone repair material of multivariant amino acid polymer-hydroxyapatite, supportive implants and preparation method. Said restorative material is made of multivariant amino acid polymers consisted with ε-aminocaproic acid and other α-amino acids, together with constituents modified hydroxyapatite, in which the constituent modified hydroxyapatite uses calcium salt as modified constituents that can be accepted in medicine and has a more solubility compared with hydroxyapatite. Modified hydroxyapatite is constructed from said calcium salt and hydroxyapatite, with a mass ratio of (2-20):(98-80), and the content of modified hydroxyapatite is 10-70% based on the mass of said bone repair material; the content of ε-aminocaproic acid in multivariant amino acid polymers is 60-99% based on the total molar quantity of multivariant amino acid polymers.

Provided is a compression resistant implant configured to fit at or near a bone defect to promote bone growth. The compression resistant implant comprises a biodegradable polymer in an amount of about 0.1 wt % to about 20 wt % of the implant and a freeze-dried oxysterol in an amount of about 5 wt % to about 90 wt % of the implant. Methods of making and use are further provided.

Provided is a compression resistant implant configured to fit at or near a bone defect to promote bone growth. The compression resistant implant comprises a biodegradable polymer in an amount of about 0.1 wt % to about 20 wt % of the implant and a freeze-dried oxysterol in an amount of about 5 wt % to about 90 wt % of the implant. Methods of making and use are further provided.

The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein, such as clotrimazole, honokiol, magnolol, tacrolimus, pimecrolimus, sirolimus, everolimus, temsirolimus, spironolactone, fluticasone, fluticasone propionate, fluticasone furoate, linezolid, telmisartan, chlorambucil, retinol, isotretinoin, acitretin, etretinate, retinoic acid (tretinoin), teniposide, mitomycin C, cytarabine, decitabine, vinblastine, vincristine, vindesine, vinorelbine, valrubicin, doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, plicamycin, pazopanib, topotecan, camptothecin, irinotecan, sunitinib, derivatives, or salt thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.